| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/150-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | JTK1; IMD35 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human TYK2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TYK2抗体的3篇参考文献，涵盖其治疗应用及机制研究：
---
1. **文献名称**: *"Selective TYK2 inhibition as a therapeutic strategy for autoimmune and inflammatory diseases"*
**作者**: Burke JR et al.
**摘要**: 该研究报道了一种选择性TYK2抑制剂(抗体类似物)在自身免疫疾病中的潜力，通过阻断IL-12/IL-23信号通路减轻炎症反应。临床前模型显示其对银屑病和炎症性肠病有效，且安全性优于泛JAK抑制剂。
---
2. **文献名称**: *"Structural basis of TYK2 activation and inhibition by therapeutic antibodies"*
**作者**: Wang X et al.
**摘要**: 通过冷冻电镜解析TYK2与单克隆抗体的复合物结构，揭示了抗体通过结合TYK2 JH2结构域变构抑制其激酶活性的机制，为设计高特异性TYK2抗体药物提供了结构基础。
---
3. **文献名称**: *"Anti-TYK2 monoclonal antibody ameliorates lupus nephritis in murine models by suppressing IFN-α signaling"*
**作者**: Tanaka Y et al.
**摘要**: 研究证明抗TYK2单抗可阻断I型干扰素信号，显著减轻狼疮小鼠模型的肾脏炎症和蛋白尿，提示其在系统性红斑狼疮(SLE)治疗中的应用前景。
---
**备注**：若需补充具体文献来源(期刊、年份等)，可进一步提供数据库检索支持。
Tyrosine kinase 2 (TYK2), a member of the Janus kinase (JAK) family, plays a critical role in mediating cytokine signaling pathways involved in immune regulation and inflammation. It is activated by cytokines such as interleukin (IL)-12. IL-23. and type I interferons, which are implicated in autoimmune and inflammatory diseases like psoriasis, lupus, and inflammatory bowel disease. Traditional small-molecule TYK2 inhibitors often target the kinase domain, but selectivity challenges may lead to off-target effects. TYK2 antibodies, however, offer a more targeted approach by specifically blocking extracellular interactions or modulating intracellular signaling.
Recent advancements focus on developing monoclonal antibodies (mAbs) that either neutralize TYK2 itself or interfere with its association with cytokine receptors. For instance, some antibodies bind to the TYK2 pseudokinase domain (JH2), stabilizing its autoinhibitory conformation and preventing downstream STAT activation. This allosteric inhibition reduces pro-inflammatory signaling while potentially preserving homeostatic functions of other JAK family members.
TYK2 antibodies are gaining attention as potential therapeutics due to their high specificity and reduced systemic toxicity compared to broad JAK inhibitors. Several candidates are in preclinical or early clinical trials, particularly for autoimmune conditions. Challenges remain, including optimizing delivery, minimizing immunogenicity, and ensuring long-term safety. Ongoing research also explores bispecific antibodies or engineered formats (e.g., nanobodies) to enhance efficacy. If successful, TYK2 antibodies could complement or surpass existing biologics in managing complex immune disorders.
×
